PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMed Express, which operates as PetMeds and owns PetCareRx, reported first-quarter fiscal 2027 results for the period ended June 30th, 2026. Net sales came in at $41 million, down from $51.2 million a year earlier. Gross profit fell to $11.3 million from $14.4 million, and gross margin slipped to 27.6% from 28.2%.

The net loss narrowed to $6.1 million, or $0.28 per diluted share, from $34.2 million, or $1.65 per share, in the same quarter last year. Adjusted EBITDA loss widened slightly to $3.4 million from $2.7 million.

Cash and equivalents fell to $13.1 million as of June 30th, down roughly 39% from the $21.4 million PetMeds held on March 31st. The company cut customer acquisition costs by 15% and general and administrative expenses by nearly 14% year-over-year, trimmed advertising spend by about a third, and added 70,000 new customers. PetMeds issued no forward guidance.

Chairman and Interim CEO Leslie Campbell said the quarter reflects "continued progress toward establishing a sustainable profitability path" and that sales have "stabilized sequentially." The company also pointed to an ongoing company-wide rollout of a new SAP enterprise resource planning system as part of that effort. PetMeds has not named a permanent chief executive; Campbell has run the company on an interim basis while the board manages both the turnaround and the unsolicited buyout approach at the same time.

Why these numbers cut both ways in the takeover fight

Read in a certain light, this is a turnaround story. A net loss that narrows from $34.2 million to $6.1 million in a single year, even with revenue down almost a fifth, points to a company finally getting its cost structure under control. Customer acquisition costs fell 15%. General and administrative spending dropped nearly 14%. Advertising spend was cut by roughly a third, from $6.0 million to $4.2 million. Layered onto the ERP overhaul management has been running, the numbers support the case Campbell is making publicly: that PetMeds is on a genuine path back to profitability, not merely bleeding out more slowly.

Read the other way, this is a company shrinking its way toward solvency rather than growing its way there. Every cost line moved in the same direction: down. None of it points to reacceleration, and revenue is still falling at close to the same pace it has for several quarters. Cash fell 39% in three months, which is the backdrop against which PetMeds signed a $37 million sale-leaseback on its own headquarters five weeks before this earnings report landed. A company confident in its standalone trajectory typically funds its balance sheet with operating cash flow, not its own real estate.

At the current adjusted EBITDA burn rate, the $13.1 million cash balance covers roughly four more quarters on its own, which is precisely the kind of runway math a board wants padded before it rejects a buyout outright. That math is also why the sale-leaseback proceeds matter more than a one-time headline number: they buy time, not a fix.

That tension is exactly what SilverCape Investments is betting on. The activist investor's revised $3-a-share proposal has sat unanswered since June, and nothing in this report obviously changes SilverCape's math. A shrinking, cash-constrained pharmacy business with no forward guidance is not a company negotiating from a position of strength, whatever the loss-narrowing narrative suggests on its own.

The category context matters too. PetMeds was the original direct-to-consumer pet pharmacy, built years before today's largest pet retailers and marketplaces treated pet medication as a serious pharmacy category. That first-mover position hasn't translated into durable defensibility, and a company monetizing cost cuts and its own real estate to fund operations is a fairly clear marker of how much pressure a standalone online pharmacy model is under in a category where larger competitors can subsidize pharmacy pricing with broader retail economics. That's a useful data point for anyone weighing whether to build or expand a similar direct-to-consumer pharmacy business rather than partnering with a retailer that already has that infrastructure.

The sale-leaseback close date and SilverCape's next move

The sale-leaseback is expected to close within 120 days of its late-July signing, putting the deal on track to land by late November. That gives the board a concrete checkpoint: whether the added liquidity changes its posture toward SilverCape, and whether SilverCape responds by raising its offer, holding at $3 a share, or walking away entirely.

Two other signals are worth tracking into next quarter. PetMeds is still mid-rollout on its new SAP system, and finishing that transition without further margin erosion would support the turnaround case more than this quarter's numbers alone. The company again issued no forward guidance, leaving investors, and potentially SilverCape, without a clear read on where the business stabilizes.

Whichever way the takeover standoff resolves, the next real data point is whether second-quarter revenue shows the decline slowing or holding at the same nearly-20% pace. A slowing decline backs the turnaround story management is telling. A repeat of this quarter's drop tells the opposite one, and hands SilverCape a stronger argument for why $3 a share is a fair price for a shrinking business rather than a lowball for a recovering one.

Source: PetMeds via GlobeNewswire